Introduction

Parenteral drug delivery has long been the cornerstone for therapies that cannot be taken orally. Today, the rise of biologics, biosimilars, and personalised medicines is reshaping this landscape. These advanced therapies offer unprecedented precision in treating complex conditions, but they also introduce significant manufacturing challenges. Sensitive molecules demand stringent sterility, stability, and scalability, while patient-centric trends call for convenient delivery formats like prefilled syringes and autoinjectors.

The market for parenteral drugs is expected to grow to $1 trillion by 2034, with biologics taking over the segment’s top 10 best-selling molecules. Parenteral manufacturing is evolving rapidly meet these demands. This blog explores the key trends, technologies, and strategies enabling manufacturers to deliver safe, effective, and specialised injectable therapies.

1. Why Parenteral Manufacturing is Under Pressure

Biologics such as monoclonal antibodies, mRNA vaccines, and cell and gene therapies dominate today’s pipelines. Unlike small molecules, these large, complex structures are highly sensitive to environmental conditions, requiring controlled temperatures, precise pH, and protection from contamination. Over 95% of biologics are injectable, and are therefore highly reliant on parenteral administration, adding complexity to formulation and fill-finish operations.

In addition, personalised medicines are often produced in small batches for rare diseases and further challenge traditional high-volume manufacturing models. Facilities must now accommodate both blockbuster biologics and niche therapies, demanding flexibility without compromising sterility or quality. Regulatory expectations are also intensifying, with Annex 1 revisions and global harmonisation efforts requiring advanced contamination control and real-time process monitoring.

These pressures are driving investment in cutting-edge technologies and strategic partnerships with CDMOs that can offer specialised capabilities.

2. Key Innovations Transforming Parenteral Manufacturing

a) Advanced Facility Design and Single-Use Technologies

Traditional stainless-steel systems are giving way to modular cleanrooms and single-use technologies (SUT). These disposable systems reduce cleaning validation, minimise cross-contamination risk, and enable faster changeovers, which is ideal for biologics and personalised therapies.

b) Continuous Manufacturing for Injectables

While batch processing has been the norm, continuous manufacturing is gaining traction for parenterals. This approach eliminates batch-to-batch variability, improves scalability, and supports rapid response to fluctuating demand. However, adoption requires significant capital investment and regulatory clarity, making it a long-term but transformative trend.

As the industry moves toward continuous manufacturing for parenterals, container closure systems (CCS) become a critical consideration. These systems which include pre-filled syringes, cartridges, and vials, are integral to maintaining sterility, product integrity, and patient safety throughout the drug’s lifecycle.

Why CCS Matters in Continuous Manufacturing:

• Sterility Assurance: Continuous processes often involve high-throughput environments, making robust CCS essential to prevent contamination.
• Compatibility with Automation: Pre-filled syringes and cartridges align well with automated filling lines, reducing human intervention and supporting the efficiency goals of continuous manufacturing.
• Regulatory Compliance: Regulatory bodies require validated CCS that demonstrate container-closure integrity under stress conditions. This adds complexity when integrating CCS into new manufacturing paradigms.
• Patient-Centric Design: Pre-filled formats improve ease of administration, reduce dosing errors, and support self-administration trends. Key drivers in modern healthcare.

c) Aseptic Spray Drying: A Game-Changer for Biologics

Aseptic spray drying is emerging as a viable alternative to freeze-drying for stabilising biologics. This process converts liquid formulations into sterile powders without terminal sterilisation, making it ideal for heat-sensitive molecules. Benefits include:

• Faster processing times compared to lyophilisation
• Lower capital and operating costs
• Controlled particle size distribution, improving consistency and bioavailability
• Versatility for vaccines, inhalable medicines, and customised therapies

Maintaining sterility throughout the spray drying process is critical, requiring closed-loop systems, HEPA filtration, and contamination-free atomisation. As regulatory bodies emphasise sterility assurance, aseptic spray drying offers a scalable, cost-effective solution for next-generation injectables.

3. Compliance with Annex 1

The revised EU GMP Annex 1 regulations have clarified regulatory expectations for sterile pharmaceutical manufacturing. Key requirements include:

• Formal Contamination Control Strategy (CCS): A holistic plan covering facility design, equipment, personnel, and process monitoring.
• Barrier Technologies: Adoption of solid-wall isolators and Restricted Access Barrier Systems (RABS) to minimise human intervention.
• Enhanced Environmental Monitoring: Stricter cleanroom classification and real-time contamination detection.
• Aseptic Process Simulations (APS): More rigorous media fill validation to demonstrate sterility assurance.
• Quality Risk Management (QRM): Risk-based decision-making embedded throughout operations.

For CDMOs and manufacturers, Annex 1 compliance is a competitive differentiator. Facilities that integrate closed systems, robust CCS, and advanced aseptic techniques will be best positioned to meet the growing demand for biologics and personalised medicines.

4. Overcoming Challenges in Manufacturing Sensitive Formulations

Impact on Facility Design:

Annex 1 compliance has driven facility redesigns to minimise contamination risk. These include segregated cleanrooms, improved airflow systems, and controlled material/personnel flows. Additionally, barrier technologies (RABS, isolators) are now standard for aseptic processing.

For CDMOs, there is a considerable challenge with implementing Annex-1 on older facilities, as retrofitting older facilities is sometimes more complex than fitting new facilities. These challenges include space constraints for isolators and new air handling units, and an additional validation burden as every modification needs requalification.

Many CDMOs opt for modular cleanroom pods or new builds to meet Annex 1 without compromising timelines. However, CDMOs with older facilities face retrofitting challenges, including upgrading the HVAC, cleanroom classifications, and automation without disrupting ongoing operations, in addition to increased CAPEX and downtime planning. For new builds, CDMOs might consider future-proofing designs with flexibility for multiple dosage forms.

Change-In and Change-Out:

Annex 1 highlights the importance of controlled entry and exit through airlocks and gowning rooms, supported by strict protocols. It also requires secure material transfer systems, such as rapid transfer ports, to minimise contamination risks. These measures can affect workflow efficiency and demand thorough training to ensure behavioural compliance.

However, challenges can be overcome through clear SOPs, regular refresher training, and integrating ergonomic design into facilities to streamline processes without compromising sterility.

Industry Bottlenecks: Small Batch Sizes

Annex 1 has thorough requirements for sterile manufacturing, which has unintentionally created a bottleneck for small innovators. These guidelines demand controlled environments, specialised equipment, and rigorous compliance, making sterile facilities expensive and capacity limited. As a result, traditional CDMOs often prioritise large commercial batches to maximise efficiency and return on investment, leaving smaller-scale clinical projects waiting for scarce production slots.

This delay is a major challenge for innovators who need rapid access to clinical trial material to maintain development timelines.

4. The Future Outlook

The parenteral manufacturing sector is entering an era of unprecedented innovation, driven by biologics, biosimilars, and personalised therapies. Manufacturers that embrace flexible facilities, digitalisation, and patient-centric delivery will be best positioned to thrive.

Ultimately, the convergence of advanced technologies and strategic partnerships will enable the industry to deliver complex therapies safely, efficiently, and at scale, meeting the needs of patients worldwide.